Pfizer Inc. (PFE)
Qualcomm CEO Is Set to Meet China's Xi. Pfizer and FedEx CEOs Are Also Heading to Beijing.
President Xi plans to meet with Qualcomm and Saudi Aramco CEOs following this year's China Development Forum, according to media reports.
Pfizer Has a New Playbook for Reviving Sales—and It's Starting to Pay Off
The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic slump.
Calls of the Day: Invitation Homes, Pfizer and Roblox
The Investment Committee debate the latest Calls of the Day.
Pfizer: Undervalued Safe Haven In Risk-Off Market
Pfizer remained flat while the S&P 500 dropped 2.25%, reinforcing its defensive strength in a risk-off market. CY24 revenue reached $63.6B (+6.7% YoY), with non-COVID sales growing 12%, exceeding expectations of 9%-11%. R&D pipeline advanced with 12 approvals, 7 pivotal study starts, and 8 Phase 3 readouts, boosting oncology and obesity treatments.
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
BioNTech SE BNTX on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents.
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.
Pfizer appoints James List to lead development of obesity medicines
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, which includes development of cardiovascular and obesity medicines.
Final Trades: Pfizer, Paychex and the JEPI
The Investment Committee debates their Final Trades.
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.
Pfizer: It's Time To Play Defensive
Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely to be quite positive for Pfizer, as the optimism around growth stocks is fading. Patent cliff risks exist, but Pfizer's substantial R&D investments and solid fundamentals make it a compelling high-yield investment.
